Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes
Background: Literature supports short-term efficacy and safety of Sensor Augmented Insulin Pump (SAP) therapy in patients with type 1 diabetes (T1D). However, no data are available showing long-term outcomes. Our study describes the long-term outcomes of SAP therapy with low-glucose suspend featur...
| Autor Principal: | Marín Carrillo, Lisseth Fernanda |
|---|---|
| Formato: | Trabajo de grado |
| Publicado: |
Pontificia Universidad Javeriana
2019
|
| Materias: | |
| Acceso en línea: |
http://hdl.handle.net/10554/41055 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: |
Background: Literature supports short-term efficacy and safety of Sensor Augmented Insulin Pump (SAP)
therapy in patients with type 1 diabetes (T1D). However, no data are available showing long-term outcomes.
Our study describes the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in
hypoglycemia in a Colombian population with T1D and hypoglycemia.
Methods: A cohort study was conducted with T1D patients receiving SAP+LGS therapy who initiated this
therapy because of hypoglycemia at San Ignacio University Hospital diabetes center in Bogota´, Colombia.
Glycated hemoglobin (A1c) was assessed at least every 6 months, severe hypoglycemia (SH) and hypoglycemia
unawareness (HU) incidence yearly. Adherence to therapy was also evaluated.
Results: One hundred eleven patients were included in the analysis. Total daily insulin dose was reduced during
follow-up (mean difference -0.22 U/kg; 95% confidence interval [CI] -0.18 to -0.26; P < 0.001). A1c levels
were reduced from a baseline value of 8.8% – 1.9% to 7.5% – 1.0% at 5 months (mean difference -1.3%; 95%
CI -1.09 to -1.50; P < 0.001) and 7.1% – 0.8% (mean difference -1.7%; 95% CI -1.59 to -1.90; P < 0.001) at
the end of follow-up (47 months on average). The incidence of SH and HU episodes decreased significantly
since the first year, and this effect was maintained over time (P < 0.001).
Conclusions: SAP+LGS therapy in T1D patients with hypoglycemia led to a significant and sustained decrease
in A1c during long periods of follow-up, as well as a significant reduction in SH and HU. Future randomized clinical trials are desired. |
|---|